Kornimate/medical-research-clean huggingface dataset:
lung ultrasound artefact analysis for exclusion of acute rejection in lung transplant recipients

Conditions: Post-Lung Transplantation Bronchiectasis

Summary: this study is being done to study a safe and non-invasive way to diagnose lung rejection and infection.

lung transplant recipients are at high risk for lung rejection and lung infection after transplant. this is diagnosed by performing lung bronchoscopies and lung biopsies. these procedures carry an increased risk for complications and are costly. this study is being done to study a safe and non-invasive way to diagnose lung rejection and infection.

Eligibility criteria:
inclusion criteria: * adult patients (\> 18 yrs) who had undergone single/double/heart-lung transplant * asymptomatic * normal spirometry defined as a fev1 without significant drop from baseline (significant drop = \>10% decrease from baseline) * clear chest radiograph over allograft exclusion criteria: * patients who are unable to consent for the procedure * patients with subcutaneous emphysema or other technical challenges that could interfere with satisfactory image acquisition- as deemed by the operator.

Keywords: post lung transplant lung bronchoscopy lung biopsy lung rejection
general anesthetic mode and postoperative complications

Conditions: Anesthesia

Summary: the relationship between anesthetic medication and postoperative major cardiac and cerebral complications will be studied using logistic regression model.

the study group try to find out if there is a connection between the use of different anesthetic methods with different narcotic drugs and postoperative major cardiac and cerebral complications.

Eligibility criteria:
inclusion criteria: * non-cardiac surgery, with age\> = 18 years old, asa grade i-iv, under general anesthesia exclusion criteria: * non-general anesthesia, without the use of target-controlled infusion of remifentanil or sufentanil, absence of intraoperative or perioperative information.
late effects and hrqol in survivors of allo-hsct - a cross sectional study

Conditions: Hematological Diseases

Summary: the cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-hsct in denmark. further, identify demographic, medical or personal factors associated with better self-reported health and quality of life.

objective the cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-hsct in denmark. further, identify demographic, medical or personal factors associated with better self-reported health and quality of life. method an observational, descriptive, cross-sectional study using clinical data and self-reported questionnaires to assess the occurrence of comorbidities and self-reported late effects in survivors treated with allo-hsct in denmark between 1970 and 2024. study population all survivors treated for malignant or non-malignant hematological disease with allo-hcst at the age of 18-79 years from 1970-2024 in denmark are eligible (n=1.436). endpoints * self-reported survivorship specific hrqol measured by eortc-qol- survivorship 100. * degree of health literacy measured by the health literacy questionnaire (hlq). * occurrence or degree of chronic graft versus host disease measured by modified lee chronic graft versus host disease symptom scale.

Eligibility criteria:
inclusion criteria: * all survivors treated for malignant or non-malignant hematological disease with allogeneic hematopoietic stem cell transplantation at the age of 18-79 years from 1970-2024 in denmark are eligible exclusion criteria: * patient unable to read and understand danish are excluded from study participation

Keywords: late effects. survivorship. allo-hsct
optimize first-line treatment for al amyloidosis with t (11; 14)

Conditions: Amyloidosis; Systemic; AL Amyloidosis

Summary: achievement of complete hematologic response (chr) is vital for systemic al amyloidosis. currently, the chr rate of daratumumab, bortezomib, and dexamethasone (dbd) is close to 60%. considering that bcl-2 inhibitor is effective for al amyloidosis with t(11; 14) and the median hematologic onset time of dbd is 7 days. we design a a prospective study on al amyloidosis with t(11; 14). all patients receive dbd at the beginning. patient will receive dbd for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.

the goal of this clinical trial is to optimize the first line treatment for systemic al amyloidosis with t(11;14). the aim of this study is to pursue early complete hematologic response. the primary endpoint is overall complete hematologic response (chr) rate at 6 months. participants will be treated according to the hematologic response after 7 days. if the patient get rapid response after 7 days, he/she will receive daratumumab, venetoclax and dexamethasone (dbd) for at least 6 cycles. if the patient do not get rapid response, he/she will receive daratumumab, venetoclax and dexamethasone.

Eligibility criteria:
inclusion criteria: 1. diagnosis of systemic al amyloidosis; 2. daratumumab, bortezomib, dexamethasone used in 1st line treatment; 3. life expectancy greater than 12 weeks; 4. hgb ≥70g/l; 5. blood oxygen saturation \>90%; 6. total bilirubin (tbil) ≤3×upper limit of normal (uln); aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤3.0×uln; 7. informed consent explained to, understood by and signed by the patient. exclusion criteria: 1. fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma. 2. presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis; 3. severe or persistent infection that cannot be effectively controlled; 4. presence of severe autoimmune diseases or immunodeficiency disease; 5. patients with active hepatitis b or hepatitis c (\[hbvdna+\] or \[hcvrna+\]); 6. patients with hiv infection or syphilis infection; 7. any situations that the researchers believe will increase the risks for the subject or affect the results of the study.

Keywords: t(11;14) rapid response al amyloidosis
efficacy and safety of oral alitretinoin (toctino®) in the treatment of patients with cutaneous lupus erythematosus

Conditions: Lupus Erythematosus, Cutaneous

Summary: to evaluate the therapeutic effect of oral alitretinoin (toctino®) in the treatment of cle with respect to proportion of responders based on the revised cutaneous lupus disease area and severity index (rclasi) activity score for skin lesions at baseline and after 24 weeks of treatment or at the latest assessment for patients who withdrew prematurely. response is defined as a reduction of 50% in the total rclasi compared to the baseline value ("rclasi 50").


Eligibility criteria:
inclusion criteria: * a clinical and histological diagnosis of cle (dle, scle, let) who failed to respond to topical corticosteroids; * total rclasi activity score of skin lesions \>6 (at least 3 points in at least 2 locations); * at least one primary but preferably 2 methods of contraception; exclusion criteria: * systemic lupus erythematosus (sle) with major systemic organ involvement, e.g. clinical significant renal involvement, requiring systemic medical treatment for the disease; * clinically significant illness that may influence the outcome of the study in the four weeks before and during the study; * active severe infection diseases, including chronic or localized; * patients with hepatic insufficiency (ast, alt \> 2.5 x uln), severe renal failure (creatinine clearance \< 60ml/min), or hypercholesterolemia characterized by: 1. fasting triglyceridemia \> 1.5 x upper limit of normal (uln) 2. fasting total cholesterol \> 1.5 x uln 3. fasting low-density lipoprotein (ldl) cholesterol \> 1.5x uln * patients with known hypersensitivity to other retinoids or vitamin a derivatives, or to any study medication component, especially soybean oil and partly hydrogenated soybean oil; * patients with cardiovascular risk factors that would exclude a starting dose of 30 mg of alitretinoin; * topical corticosteroids within 14 days prior to dosing; * patients treated with any systemic or topical retinoids within 4 weeks before start of study treatment; * drugs with a potential for drug-drug interaction, such as systemic tetracyclines, ketoconazole, or st. john"s wort within 1 week, or receiving systemic itraconazole within 2 weeks, before start of study treatment; * initiation or change in the dose of any current systemic medication for the treatment of cle/sle prior to the study (time depending on drug class and half-life); * treatment with immunosuppressive drugs for other reasons, 4 weeks prior and within the study; * concomitant medication with drugs with a known photosensitizing potential, e.g. tetracyclines, griseofulvin, thiazides, furosemide, sulfonamides or tolbutamide; * drugs associated to cle-induction: terbinafine, hydrochlorothiazide, diltiazem, verapamil, nifedipine, nitrendipine, fluorouracil, penicillamine, infliximab, adalimumab, etanercept, pantoprazole; other protocol-defined inclusion/exclusion criteria may apply

Keywords: cutaneous lupus erythematosus discoid lupus erythematosus subacute cutaneous lupus erythematosus lupus erythematosus tumidus
structural and functional brain reorganization in neuropathic pain. influences of the loss of sensitivity and the atrophy cortical on activations due to stimulation allodynic

Conditions: Neuropathic Pain

Summary: neuropathic pain is a medical condition involving allodynia (painful perceptions in response to stimuli that normally are not) and spontaneous pain (occurring at rest, without stimulation). this pain is secondary to nervous system injury affecting the sensory system. the lesion is either at the nerve endings of the spinal cord or brain. it induces a loss of sensitivity and reorganization of brain activity. previous studies in functional neuroimaging have focused on brain areas activated during allodynic stimuli compared to non-painful stimuli. the abnormalities have been reported, but it was not possible to conclude formally. the objective of this study is to understand the brain dysfunction that induces allodynic pain considering the deafferentation of each patient and possible cortical losses.


Eligibility criteria:
inclusion criteria: * with neuropathic pain * in the case of central lesions, the lesion must be unique and small * treatment not stable opioid for one week * consent signed exclusion criteria: * severe psychiatric history * presence of an evolutive lesion, expansive, cancerous or tumorous underlying * patient needing of opioid therapy * contraindication at mri scan
metformin in preventing androgen deprivation therapy induced insulin resistance and metabolic syndrome

Conditions: Metabolic Syndrome; Hypercholesterolemia

Summary: the main purpose of this study is to assess the efficacy of metformin in abrogating androgen deprivation therapy (adt) induced insulin resistance as measured by homeostasis model assessment (homair) in men with non-metastatic prostate cancer.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * ecog ≤ 1 * histologically confirmed prostate cancer of early or locally advanced stage, or metastatic prostate cancer with bone involvement only (≤ 5 sites of bone metastases only) * plan to receive ≥ 6 months continuous androgen deprivation therapy by a gnrh agonist * patients who are to receive antiandrogens with gnrh agonists are not excluded from the study. but the form, dose and duration of antiandrogen treatment should be recorded. * adequate renal function (creatinine ≤ 177mmol/l and gfr \>30 mls/min ) * adequate hepatic function (bilirubin must be ≤ 1.5 x upper limit of normal range, alt and alp must be ≤ 2.5 x upper limit of normal) exclusion criteria: * visceral involvement * \> 5 sites of bone metastases * history of confirmed diabetes mellitus (patients with impaired fasting glucose or impaired glucose intolerance will not be excluded) 12 * treatment with medications that may alter glucose or insulin level within 3 months (including insulin, oral hypoglycemic agents, systemic corticosteroid of any dosage, atypical antipsychotic drugs of any dose) * malignant disease other than prostate cancer at the time of enrolment * bilateral orchiectomy * previous androgen deprivation therapy by a gnrh agonist or anti-androgen within last 12 months(patient who had a gnrh agonist more than 12 months ago are allowed if their testosterone levels are in the normal range at the time of recruitment) * chemotherapy within 6 months * history of lactic acidosis * cardiac or respiratory insufficiency, severe infection that is likely to increase the risk of lactic acidosis * medical or psychiatric conditions that compromise the patient's ability to give informed consent

Keywords: body fat mass gain insulin resistance
drug-drug interaction study with rifampin

Conditions: Alzheimer Disease

Summary: the purpose of the study is to determine if the concomitant administration of rifampin with bms-708163 will affect the pharmacokinetics of bms-708163 and to assess safety and tolerability of co-administration bms-708163 and rifampin


Eligibility criteria:
inclusion criteria: * healthy male and postmenopausal female subjects, 18-55 yrs old inclusive exclusion criteria: * women of childbearing potential * tuberculosis
the maternal cellular immune system and cytomegalovirus intrauterine infection

Conditions: Pregnant Women; Cytomegalovirus Infections

Summary: the purpose of this study is to find a correlation between function of cytomegalovirus -specific t cells and the probability for intrauterine transmission.

fetal infection with cmv is the most common cause of intrauterine infection. only 40% of pregnant women with primary cmv transmit the virus to their fetus. many of these women are referred to amniocentesis and many elect to terminate pregnancy without knowledge about fetal infection or damage. currently it is assumed that transmission is dictated by variety of factors including maternal and fetal immune system. efforts to find correlation between maternal immune system and fetal infection which can be used as a diagnostic marker were unsuccessful. our hypothesis is that there is a correlation between cellular immune response of the mother to cmv infection and viral transmission to the fetus. pregnant women with primary cmv infection (40% of whom are expected to be transmitters)and with pre-conception immunity will participate in this study. blood from these women will be incubated with cmv peptides and t cell activation will be measured by the secretion of various cytokines.

Eligibility criteria:
inclusion criteria: * pregnant women * cmv igg sero-conversion or the presence of low avidity igg antibodies or the presence of igm with no previous igg antibodies. exclusion criteria: * underlying immune deficiencies * other pregnancy complications

Keywords: cytomegalovirus infections pregnancy t-lymphocytes transmission
trial comparing part-time versus minimal-time patching for moderate amblyopia

Conditions: Amblyopia

Summary: the goals of this study are: * to determine whether the visual acuity improvement obtained with part-time (6 hours) patching is equivalent to the visual acuity improvement obtained with minimal patching (2 hours) for moderate amblyopia. * to develop more precise estimates than currently available for the visual acuity improvement that occurs during treatment of amblyopia with patching. * to identify factors that may be associated with successful treatment of amblyopia with patching.

amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. patching has been the mainstay of amblyopia therapy. it is generally held that the response to treatment is best when it is instituted at an early age, particularly by age two or three, and is poor when attempted after eight years of age. for moderate amblyopia, patching is the most commonly prescribed treatment although other modalities such as atropine penalization are also prescribed. there is no specific patching regimen that is widely accepted for treatment of moderate amblyopia and limited or no data available to favor the use of one specific regimen; both minimal occlusion (e.g., 2 hours per day) and six or more hours per day of patching are prescribed in clinical practice. the study is a randomized trial comparing daily patching regimes for children with moderate amblyopia. it will consist of about 160 children. patients in the moderate (20/40-20/80) group will patch part-time (6 hours) or minimal time (2 hours) of each day for the 4-month study period. there are at least two follow up visits during the 4-month period. visual acuity is the major study outcome. it is assessed at the 4-month exam.

Eligibility criteria:
inclusion criteria: * patients must be less than 7 years of age with the original cause of amblyopia as strabismus or anisometropia. * visual acuity in the amblyopic eye must be between 20/40 and 20/80. * visual acuity in the sound eye of 20/40 or better. * there must be at least 3 lines of acuity difference between the two eyes. exclusion criteria: * patching treatment (other than spectacles) within six months prior to enrollment and other amblyopia treatment of any type used within one month prior to enrollment.
clinical trial to investigate the efficacy and safety of nusepin® in covid-19 pneumonia patients

Conditions: COVID19 Pneumonia

Summary: a randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of nusepin® intravenous infusion in covid-19 pneumonia patients


Eligibility criteria:
inclusion criteria 1. male or female subjects aged between 18≤ and \<80 years old 2. laboratory-confirmed sars-cov-2 infection by pcr test for the first time within 144 hours prior to randomization 3. diagnosis of pneumonia based on: * radiographic infiltrates by imaging (chest x-ray, ct scan) and * 3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum (all day), tachypnea, dyspnea, pleuritic chest pain and * crp value \> 10 mg/l 4. patients with blood leukocyte count \> 4.0 x 109 /l and lymphocyte count \> 0.7 x 109 * l 5. patients with spo2 ≤ 94% on room air or pa02/fi02 ratio \< 300mghg at screening 6. patients capable to give consent and who have signed the informed consent form before any trial related assessment. 7. medically accepted effective contraception for women of childbearing potential (wocbp) which should be continued until at least 90 days after the last dose of trial treatment. 8. patients with news2 score \> 7 exclusion criteria 1. alanine transaminase (alt) or aspartate transaminase (ast) \> 5 times the upper limit of normal. 2. reduced renal function with estimated glomerular filtration rate (egfr) \< 30 ml/min or hemodialysis or hemofiltration. 3. pregnancy or breast feeding. 4. evidence of multiorgan failure 5. steroid treatment by any reason within 72 hours prior to enrolment 6. participation in any other clinical trial of an experimental agent treatment for covid-19 7. physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.
thoracolumbar brace for individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: this pilot study looked to see if a new brace would change the way people with parkinson's disease positioned their bodies. it also gathered information on the experience of wearing the brace.


Eligibility criteria:
inclusion criteria: * 50-80 years of age * diagnosed with parkinson's disease * participant self-reports mild difficulty with posture * independent in ambulation without an assistive device (i.e., no walker or cane) * able to give consent determined via telephone screen assessment or at minimum can follow simple directions * able to tolerate 5 minutes of standing or walking at a time per self-report exclusion criteria: * rigid or fixed spine, as determined by self-report and use of thoracolumbar flexibility screen * symptoms present before the age of 50 * other neurologic diagnosis, as determined by self-report * spinal surgery * lives in a nursing home or skilled facility * uncorrected vision loss * skin that is sensitive to tape or extremely fragile * recent surgery (within the last 3 months) that affects mobility, as determined by self-report * chest pain at rest or with activity per self report * shortness of breath with daily activity per self report * severe orthostatic hypotension assessed during in-person screen with sitting and standing blood pressure, evidenced by a 20-point drop in systolic blood pressure or 10-point drop in diastolic blood pressure and symptoms (e.g., dizziness) that don't resolve in 5 minutes. * high blood pressure 180/110 resting or systolic blood pressure \<90 mmhg * resting heart rate \> 100 bpm or \<50 bpm * waist circumference \ 51" that would prevent proper fitting of calibrace.
correlation between bmi and craniovertebral angle and their impact on hand grip strength and neck functional disability in egyptian university student

Conditions: Neck Pain

Summary: objective: to find the relation between cranio-vertebral angle and hand grip strength in university student mobile users. design: cross sectional study. setting: ahram candian university subjects:100 male and female university students with age ranged from 20 to 30 years old will participate in this study. intervention: cross sectional study to detect the relation between cranio-vertebral angle and hand grip strength in university student mobile users. main measures: * fhp app (pyeongtaek, south korea) mobile application * hand dynamometer (the jamar® hydraulic hand) (lupton-smith et al.,2022) * mechanical height and weight scale * visual analogue scale * arabic neck disability index results: the results will be obtained via one-way analyses of variance (anova).


Eligibility criteria:
inclusion criteria: * • their ages will range from 20-30 years old. * their bmi will be between than 20- 30kg/m2. * all of them suffer from mild degree of neck pain. * the subjects complain from neck pain for 1 month ago * exclusion criteria: exclusion criteria were a history of any of the following condition: * inflammatory diseases or any rheumatic disorders, * a history of vertebral fractures * surgical spinal fixation. * •any neurological disorders like ms
safety and pharmacokinetics study of new formulation of bimatoprost in patients with alopecia

Conditions: Alopecia; Alopecia, Androgenetic; Baldness

Summary: this study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. two formulations of bimatoprost will be investigated in part 1 and a third formulation of bimatoprost will be investigated in part 2. part 2 will begin after part 1 has completed.


Eligibility criteria:
inclusion criteria: * males with moderate male-pattern baldness (androgenic alopecia) * females with moderate female pattern hair loss * non-smoker or smoker with at least 30 days abstinence from smoking/using nicotine-containing products exclusion criteria: * any dermatological condition of the scalp other than androgenic alopecia (males) or female pattern hair loss (females) * use of bimatoprost or other prostaglandin analogs within 3 months * prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months * any prior hair growth procedures (eg, hair transplant or laser) * blood donation or equivalent blood loss within 90 days * history of alcohol or drug addiction